Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
GNGenelux Corporation logo

Genelux Corporation (GNLX)

NASDAQ Global Market · Currency in USD
$2.00 ▲ +0.02 (+1.01%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.13 ▲ +0.13 (+6.50%)
Pre-market: Oct 26, 7:06 AM ET

Summary

Previous Close
$1.98
Open
$1.98
Day's Range
$1.94 – $2.03
52 Week Range
$1.90 – $8.54
Volume
648,745
Avg. Volume
285,104
Market Cap
$90.49M
Beta (5Y Monthly)
0.58
PE Ratio (TTM)
--
EPS (TTM)
-$0.75
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$17.33

Profile: Genelux Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
26
CEO
Thomas D. Zindrick

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.20
DateEst.Actual
Aug 13, 2026-$0.20-$0.21Miss
May 7, 2026-$0.18-$0.20Miss
Mar 19, 2026-$0.22-$0.24Miss
Nov 5, 2025-$0.23-$0.21Beat
Aug 7, 2025-$0.22-$0.20Beat
May 6, 2025-$0.24-$0.21Beat

Analyst view

Consensus price target
$17.33 ▲ +766.5%
Range $16.00 – $20.00
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on GNLX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.